Ophthalmology Times23h
Alumis and Acelyrin file a definitive proxy statement for proposed merger
Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...
Le Lézard2d
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheetBoards unanimously recommend stockholders ...
Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...
Pliant Therapeutics: An Activist On Deck
Pliant Therapeutics' stock plummeted, but Kevin Tang’s stake raises takeover hopes. Find out why PLRX stock’s cash reserves ...
Fierce Biotech5d
Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts
While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...
Le Lézard6d
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...